Antitumour agents as inhibitors of tryptophan 2,3-dioxygenase

Biochemical and Biophysical Research Communications

Volumn 443, Issue 1, 2014, Pages 28-31

  Pantouris, Georgios ^a   Mowat, Christopher G ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Cancer; Kynurenine pathway; Tryptophan 2,3 dioxygenase

Indexed keywords

ANTINEOPLASTIC AGENT; BETA LAPACHONE; DEZAGUANINE; MITOMYCIN; NSC 111041; NSC 255109; NSC 26326; NSC 267461; NSC 36398; OXYGENASE INHIBITOR; TAXIFOLIN; TRYPTOPHAN 2,3 DIOXYGENASE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; COLON CANCER; HUMAN; IN VITRO STUDY; KIDNEY CANCER; LEUKEMIA; LUNG NON SMALL CELL CANCER; MELANOMA; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RETINOBLASTOMA;

CANCER; HUMAN INDOLEAMINE 2,3-DIOXYGENASE; HUMAN TRYPTOPHAN 2,3-DIOXYGENASE; IDO; KMO; KYNURENINE 3-MONOXYGENASE; KYNURENINE PATHWAY; NATIONAL CANCER INSTITUTE USA; NCI; TDO; TRYPTOPHAN 2,3-DIOXYGENASE;

ANTINEOPLASTIC AGENTS; CATECHOLS; CELL LINE, TUMOR; CHROMONES; HUMANS; QUERCETIN; TRYPTOPHAN OXYGENASE;

EID: 84890857180     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.11.037     Document Type: Article

References (31)

1. Kotake Y., Masayama T. Über den mechanismus der kynurenin-bildung aus tryptophan. Z. Physiol. Chem. 1936, 243:237-244.
2. Knox W.E., Mehler A.H. The conversion of tryptophan to kynurenine in liver. I. The coupled tryptophan peroxidase-oxidase system forming formylkynurenine. J. Biol. Chem. 1950, 187:419-430.
3. Minatogawa Y., Suzuki S., Ando Y., Tone S., Takikawa O. Tryptophan pyrrole ring cleavage enzymes in placenta. Adv. Exp. Med. Biol. 2003, 527:425-434.
4. Tatsumi K., Higuchi T., Fujiwara H., Nakayama T., Egawa H., Itoh K., Fujii S., Fujita J. Induction of tryptophan 2,3-dioxygenase in the mouse endometrium during implantation. Biochem. Biophys. Res. Commun. 2000, 274:166-170.
5. Britan A., Maffre V., Tone S., Drevet J.R. Quantitative and spatial differences in the expression of tryptophan-metabolizing enzymes in mouse epididymis. Cell Tissue Res. 2006, 324:301-310.
6. Haber R., Bessette D., Hulihan-Giblin B., Durcan M.J., Goldman D. Identification of tryptophan 2,3-dioxygenase RNA in rodent brain. J. Neurochem. 1993, 60:1159-1162.
7. Yamamoto S., Hayaishi O. Tryptophan pyrrolase of rabbit intestine: d- and l-tryptophan-cleaving enzyme or enzymes. J. Biol. Chem. 1967, 242:5260-5266.
8. Munn D.H., Zhou M., Attwood J.T., Bondarev I., Conway S.J., Marshall B., Brown C., Mellor A.L. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998, 281:1191-1193.
9. Steinman R.M., Banchereau J. Taking dendritic cells into medicine. Nature 2007, 449:419-426.
10. Löb S., Königsrainer A., Rammensee H.-G., Opelz G., Terness P. Opinion: inhibitors of indoleamine 2,3-dioxygenase for cancer therapy: can we see the wood for the trees?. Nat. Rev. Cancer 2009, 9:445-452.
11. Muller A.J., DuHadaway J.B., Donover P.S., Sutanto-Ward E., Prendergast G.C. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med. 2005, 11:312-319.
12. Pucchio T.D., Danese S., Cristofaro R.D., Rutella S. Inhibition of indoleamine 2,3-dioxygenase: a review of novel patented lead compounds. Expert Opin. Ther. Pat. 2010, 20:229-250.
13. Banerjee T., DuHadaway J.B., Gaspari P., Sutanto-Ward E., Munn D.H., Mellor A.L., Malachowski W.P., Prendergast G.C., Muller A.J. A key in vivo antitumour mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase. Oncogene 2008, 27:2851-2857.
14. Kumar S., Malachowski W.P., DuHadaway J.B., LaLonde J.M., Carroll P.J., Jaller D., Metz R., Prendergast G.C., Muller A.J. Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J. Med. Chem. 2008, 51:1706-1718.
15. Pereira A., Vottero E., Roberge M., Mauk A.G., Andersen R.J. Indoleamine 2,3-dioxygenase inhibitors from the Northeastern Pacific marine hydroid Garveia annulata. J. Nat. Prod. 2006, 69:1496-1499.
16. Opitz C.A., Litzenburger U.M., Sahm F., Ott M., Tritschler I., Trump S., Schumacher T., Jestaedt L., Schrenk D., Weller M., Jugold M., Guillemin G.J., Miller C.L., Lutz C., Radlwimmer B., Lehmann I., Deimling A.V., Wick W., Platten M. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 2011, 478:197-203.
17. Pilotte L., Larrieu P., Stroobant V., Colau D., Dolusic E., Frédérick R., De Plaen E., Uyttenhove C., Wouters J., Masereel B., Van den Eynde B.J. Reversal of tumoural immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:2497-2502.
18. Basran J., Rafice S.A., Chauhan N., Efimov I., Cheesman M.R., Ghamsari L., Raven E.L. A kinetic, spectroscopic, and redox study of human tryptophan 2,3-dioxygenase. Biochemistry 2008, 47:4752-4760.
19. Chauhan N., Basran J., Efimov I., Svistunenko D.A., Seward H.E., Moody P.C., Raven E.L. The role of serine 167 in human indoleamine 2,3-dioxygenase: a comparison with tryptophan 2,3-dioxygenase. Biochemistry 2008, 47:4761-4769.
20. Takikawa O., Kuroiwa T., Yamazaki F., Kido R. Mechanism of interferon-gamma action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-gamma and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity. J. Biol. Chem. 1988, 263:2041-2048.
21. Bentle M.S., Reinicke K.E., Dong Y., Bey E.A., Boothman D.A. Nonhomologous end joining is essential for cellular resistance to the novel antitumour agent, β-lapachone. Cancer Res. 2007, 67:6936-6945.
22. Wuerzberger S.M., Pink J.J., Planchan S.M., Byers K.L., Bornmann W.G., Boothman D.A. Induction of apoptosis in MCF-7:WS8 breast cancer cells by β-lapachone. Cancer Res. 1998, 58:1876-1885.
23. Huang L., Pardee A.B. β-lapachone induces cell cycle arrest and apoptosis in human colon cancer cells. Mol. Med. 1999, 5:711-720.
24. Shah H.R., Conway R.M., Quill K.R.V., Madigan M.C., Howard S.A., Qi J., Weinberg V., O'Brien J.M. Beta-lapachone inhibits proliferation and induces apoptosis in retinoblastoma cell lines. Eye 2008, 22:454-460.
25. Planchon S.M., Wuerzberger S., Frydman B., Witiak D.T., Hutson P., Church D.R., Wilding G., Boothman D.A. β-lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response. Cancer Res. 1995, 55:3706-3711.
26. Bey E.A., Bentle M.S., Reinicke K.E., Dong Y., Yang C.R., Girard L., Minna J.D., Bornmann W.G., Gao J., Boothman D.A. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by β-lapachone. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:11832-11837.
27. Luo H., Jiang B.H., King S.M., Chen Y.C. Inhibition of cell growth and VEGF expression in ovarian cancer cells by flavonoids. Nutr. Cancer 2008, 60:800-809.
28. http://www.dtp.nci.nih.gov/dtpstandard/ChemData/index.jsp.
29. Lee C.-H., Hong H.-M., Chang Y.-Y., Chang W.-W. Inhibition of heat shock protein (Hsp) 27 potentiates the suppressive effect of Hsp90 inhibitors in targeting breast cancer stem-like cells. Biochimie 2012, 94:1382-1389.
30. Li L.S., Bey E.A., Dong Y., Meng J., Patra B., Yan J., Xie X.J., Brekken R.A., Barnett C.C., Bornmann W.G., Gao J., Boothman D.A. Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy. Clin. Cancer Res. 2011, 17:275-285.
31. Kuck D., Caulfield T., Lyko F., Medina-Franco J.L. Nanaomycin A selectively inhibits DNMT3B and reactivates silenced tumour suppressor genes in human cancer cells. Mol. Cancer Ther. 2010, 9:3015-3023.